Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

30
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
30
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

34
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
34
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

36
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
36
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

51
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
51
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.

Rheumatology (Oxford, England)·2026
Same author

Choosing the next option: a scenario-based roadmap for b/tsDMARD sequencing in rheumatoid arthritis.

Clinical rheumatology·2026
Same author

STING-STAT3-SOX18 Axis Drives EndMT and Epigenetic Reprogramming in SAVI Lung Fibrosis.

bioRxiv : the preprint server for biology·2026
Same author

Anifrolumab to Treat Severe Hepatic Involvement in a De Novo IFIH1 Mutation.

Journal of clinical immunology·2026
Same author

Remote personalised exercise in axial spondyloarthritis: the SPARK trial - protocol for a 6-month randomised controlled trial.

BMJ open·2026
Same author

Trajectories of Physical Function in Canadian Children With Juvenile Idiopathic Arthritis.

Arthritis care & research·2026

Related Experiment Video

Updated: Sep 6, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

331

Developing guidelines for ultrarare rheumatic disorders: a bumpy ride.

David Piskin1,2,3, Micol Romano3,4, Daniel Aletaha5

  • 1Lawson Health Research Institute, London, Ontario, Canada david.piskin@lhsc.on.ca.

Annals of the Rheumatic Diseases
|June 23, 2022
PubMed
Summary
This summary is machine-generated.

Developing clinical practice guidelines for ultrarare diseases presents unique methodological challenges due to limited physician expertise and scarce literature. This viewpoint explores these challenges to improve future guideline development for rare conditions.

Keywords:
Cryopyrin-Associated Periodic SyndromesEpidemiologyInterleukin 1 Receptor Antagonist Protein

More Related Videos

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.3K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

344

Related Experiment Videos

Last Updated: Sep 6, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

331
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.3K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

344

Area of Science:

  • Medical Informatics
  • Clinical Epidemiology
  • Rare Diseases

Background:

  • Clinical practice guidelines aid physicians and patients in healthcare decisions.
  • Standardized procedures exist for guideline development, relying on literature synthesis and expert input.
  • Developing guidelines for common diseases is well-established due to ample data and expertise.

Purpose of the Study:

  • To identify and discuss methodological challenges in creating recommendations for ultrarare diseases.
  • To propose solutions for facilitating future guideline development in the context of rare conditions.

Main Methods:

  • This viewpoint discusses challenges encountered during the development of recommendations for autoinflammatory disorders.
  • It focuses on methodological perspectives specific to ultrarare disease contexts.

Main Results:

  • Guideline development for ultrarare diseases is hindered by a scarcity of literature and limited physician familiarity.
  • Methodological approaches need adaptation to address the unique constraints of rare disease research.

Conclusions:

  • Addressing the challenges in developing guidelines for ultrarare diseases is crucial for advancing patient care.
  • Future efforts should focus on innovative methodologies to overcome data and expertise limitations in rare disease guideline creation.